Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma-Reference-Cited by-同舟云学术

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

Published:2018-08-24 Issue:1 Volume:14 Page:
ISSN:1746-6148
Container-title:BMC Veterinary Research
language:en
Short-container-title:BMC Vet Res

Author:

Sadowski Abbey R.,Gardner Heather L.,Borgatti Antonella,Wilson Heather,Vail David M.,Lachowicz Joshua,Manley Christina,Turner Avenelle,Klein Mary K.,Waite Angharad,Sahora Alexandra,London Cheryl A.^ORCID

Funder

Karyopharm Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

General Veterinary,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12917-018-1587-9.pdf

Reference22 articles.

1. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83:1021–32.

2. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol. 2012;3:137–51.

3. Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.

4. Parikh K, Cang S, Sekhri A, Delong L. Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.

5. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffma MG, Perrotti D. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122:3034–44.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Remission of Cutaneous Lymphoma in a Dog Treated with Verdinexor;Journal of the American Animal Hospital Association;2024-09-01

2. Efficacy of verdinexor for the treatment of naïve canine epitheliotropic cutaneous T‐cell lymphoma: An open‐label pilot study;Veterinary Dermatology;2024-07-29

3. Development of a UPLC-MS/MS method for quantifying KPT-335 (Verdinexor) in feline plasma for a study of PK;Frontiers in Veterinary Science;2024-07-26

4. New Therapies in Veterinary Oncology;Veterinary Clinics of North America: Small Animal Practice;2024-05

5. Novel Treatments for Lymphoma;Veterinary Clinics of North America: Small Animal Practice;2024-05